Reading ERAS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ERAS free→Reading ERAS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ERAS free→QuarterlyIQ Insights · ERAS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 11, 2026, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of S…
Other Events. On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. (“RevMed”). In the letter RevMed alleged that (1) the Company’s asset ERAS-0015 is “substantially equivalent” to certain compositions claimed in RevMed’s U.S. Patent No. 12,409,225 (the “‘225 Patent”) and that ERAS-0015 infringes the ‘225 Patent under the doctrine of equivalents; (2) that a third party misappropriated RevMed’s alleged trade secrets in connection with a patent relat…
Other Events. On April 21, 2026, Erasca, Inc. (the “Company”) narrowed the time period for the anticipated Phase 1 monotherapy data readout for the Company’s pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 clinical trials to no later than mid-May of 2026, from the prior guidance of the first half of 2026. The Company is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors, and the Company’s licensor, Guangzhou Joyo Pharmatech Co., Lt…
Results of Operations and Financial Condition. On March 12, 2026, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months and fiscal year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “fil…
Other Events. On January 20, 2026, Erasca, Inc. (the “Company”) disclosed that its cash, cash equivalents and marketable securities for the Company as of December 31, 2025 was approximately $341.8 million. On January 23, 2026, the Company announced that it closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares (the “January 2026 O…
Other Events. On January 21, 2026, Erasca, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 22,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at an offering p…
of this Form 8-K shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless otherwise expressly set forth by specific reference in such a filing. Forward-Looking Statements The Company cautions you that statements contained in this report regarding matters that are not historical facts are f…
Other Events. On January 12, 2026, the Company announced clinical progress for its RAS-targeting franchise and 2026-2027 milestones. ERAS-0015 – Potential best-in-class RAS targeting molecule • Dose escalation in ongoing AURORAS-1 Phase 1 trial advancing faster than anticipated, due to significant unmet medical need and high investigator and patient enthusiasm • Ongoing confirmed and unconfirmed responses observed in multiple patients with differing tumor types and RAS mutations o Ongoing res…
Results of Operations and Financial Condition. On November 12, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purp…
Results of Operations and Financial Condition. On August 12, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of…
Results of Operations and Financial Condition. On May 13, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended March 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of S…
Results of Operations and Financial Condition. On March 20, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months and fiscal year ended December 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “fil…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.